J&J exec says "public plan" would stymie innovation
Kathleen Buto, vice president, health policy, for Johnson & Johnson told a congressional committee the pharmaceutical industry is concerned a public health plan could undermine a market-based system that provides incentives for long-term research
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.